摘要
目的系统评价杏芎氯化钠注射液治疗缺血性脑卒中的治疗效果和安全性。方法系统检索PubMed、CNKI、万方数据库、维普、SinoMed等数据库,搜集杏芎氯化钠注射液治疗缺血性脑卒中的随机对照试验(RCT)。检索时限为建库至2018年12月,由两名专业人员分别提取材料,采用RevMan5.3软件对数据进行合并、分析,利用协作网提供的风险评价表,评价纳入的文献质量。结果共采用9篇RCT,累计共1511例患者,其中试验组756例,对照组755例。Meta分析的结果:试验组的药物治疗总有效率高于对照组[RR=1.11,95%CI(1.01,1.22),P=0.04]。试验组的神经功能缺损程度改善情况优于对照组[MD=-4.16,95%CI(-7.23,-1.10),P=0.008]。两组的Barthel指数评分比较,差异无统计学意义[MD=-0.39,95%CI(-17.29,16.50),P=0.96]。试验组的超敏C反应蛋白水平低于对照组[MD=-1.94,95%CI(-3.38,-0.51),P=0.008]。结论杏芎氯化钠注射液治疗缺血性脑卒中的效果显著,且安全性高。但目前仍缺乏更多确实可靠的药物临床试验来提供临床依据。
Objective To systematically evaluate the efficacy and safety of Xingxiong Sodium Chloride Injection in the treatment of ischemic stroke.Methods Systematic search of PubMed,CNKI,Wanfang database,Vip,SinoMed and other databases was conducted to collect randomized controlled trials(RCT)of Xingxiong Sodium Chloride Injection in the treatment of ischemic stroke.The retrieval time was from the establishment of the database to December 2018.Data was extracted by two professionals and merged and analyzed by RevMan 5.3 software.The quality of the included literature were evaluated using the risk assessment form provided by the collaborative network.Results There were 9 RCTs and 1511 patients,including 756 in experimental group and 755 in control group.Results of Meta-analysis:total effective rate of drug treatment in experimental group was higher than that in control group[RR=1.11,95%CI(1.01,1.22),P=0.04].The improvement of neurological deficit in experimental group was better than that in control group[MD=-4.16,95%CI(-7.23,-1.10),P=0.008].There was no significant difference in Barthel index score between two groups[MD=-0.39,95%CI(-17.29,16.50),P=0.96].The level of hs-CRP in experimental group was lower than that in control group[MD=-1.94,95%CI(-3.38,-0.51),P=0.008].Conclusion Xingxiong Sodium Chloride Injection is effective and safe in the treatment of ischemic stroke.However,there is still a lack of more reliable clinical trials to provide clinical evidence.
作者
余泽程
雒晓东
蔡巧娣
郑春叶
YU Zecheng;LUO Xiaodong;CAI Qiaodi;ZHENG Chunye(The Second Clinical Medical College,Guangzhou University of Chinese Medicine,Guangdong Province,Guangzhou 510405,China;Department of Neurology,Fangcun Branch,Guangdong Hospital of Traditional Chinese Medicine,Guangdong Province,Guangzhou 510370,China)
出处
《中国医药导报》
CAS
2019年第29期153-157,共5页
China Medical Herald
基金
广东省科技计划项目（2017ZC0203）
广东省中医院黄煌学术经验传承工作室（E43723）
